Serum kynurenic acid: Possible association with invasiveness of non-small cell lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 9, 2012, Pages 4241-4244

  Sagan, Dariusz ^a   Kocki, Tomasz ^a   Kocki, Janusz ^a   Szumiło, Justyna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Antiproliferative; Invasiveness; Kynurenic acid; Kynurenine; Lung cancer

Indexed keywords

KYNURENIC ACID;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CHI SQUARE DISTRIBUTION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR INVASION;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; KYNURENIC ACID; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; STATISTICS, NONPARAMETRIC;

EID: 84874013943     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.9.4741     Document Type: Article

References (23)

1. Cooke DT, Nguyen DV, Yang Y, et al (2010). Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy. Ann Thorac Surg, 90, 943-8.
2. Dai F, Liu L, Che G, et al (2010). The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer, 10, 220.
3. Detterbeck FC, Boffa DJ, Tanoue LT (2009). The new lung cancer staging system. Chest,136, 260-71.
4. DiNatale BC, Murray IA, Schroeder JC, et al (2010). Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci, 115, 89-97.
5. Foster AC (1986). Involvement of excitatory amino acid receptors in the mechanisms underlying excitotoxic phenomena. Adv Exp Med Biol, 203, 303-16.
6. Fulop F, Szatmari I, Vamos E, et al (2009). Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr Med Chem, 16, 4828-42.
7. Hoshi M, Ito H, Fujigaki H, et al (2009). Changes in serum tryptophan catabolism as an indicator of disease activity in adult T-cell leukemia/lymphoma. Leuk Lymphoma, 50, 1372-4.
8. Huang A, Fuchs D, Widner B, et al (2002). Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer, 86, 1691-6.
9. Karanikas V, Zamanakou M, Kerenidi T, et al (2007). Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther, 6, 1258-62.
10. Lob S, Konigsrainer A, Zieker D, et al (2009). IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother, 58, 153-7.
11. Maeda R, Yoshida J, Ishii G, et al (2011). Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: Patient selection criteria for adjuvant chemotherapy according to the 7th edition TNM classification. Chest, doi: 10.1378/chest.10-3279.
12. Mellor AL, Keskin DB, Johnson T, et al (2002). Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol, 168, 3771-6.
13. Munn DH, Mellor AL (2007). Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest, 117, 1147-54.
14. Munn DH, Shafizadeh E, Attwood JT, et al (1999). Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med, 189, 1363-72.
15. Schroecksnadel K, Winkler C, Fuith LC, Fuchs D (2005). Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett, 223, 323-9.
16. Suzuki Y, Suda T, Furuhashi K, et al (2010). Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer, 67, 361-5.
17. Tomaszek SC, Kim Y, Cassivi SD, et al (2011). Bronchial resection margin length and clinical outcome in non-small cell lung cancer. Eur J Cardiothorac Surg, doi:10.1016/j.ejcts.2011.02.042.
18. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (2004). Pathology and genetics of tumors of the lung, pleura, thymus and heart. WHO Classification of Tumors. 1st. ed. Lyon. IARC Press.
19. Walczak K, Browski D, Langner E, et al (2011). Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells. Scand J Gastroenterol, 46, 903-12.
20. Wang J, Simonavicius N, Wu X, et al (2006). Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem, 281, 22021-8.
21. Watanabe K, Emoto N, Hamano E, et al (2011). Genome structure-based screening identified epigenetically silenced microRNA associated with invasiveness in non-small-cell lung cancer. Int J Cancer, doi: 10.1002/ijc.26254.
22. Witkiewicz A, Williams TK, Cozzitorto J, et al (2008). Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg, 206, 849-854.
23. Zdzisinska B, Wejksza K, Walter-Croneck A, et al (2010). Kynurenic acid in blood and bone marrow plasma of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients. Leuk Res, 34, 38-45.